Drug · CHEMBL635

PREDNISONE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. PREDNISONE. Drugs and targets, record CHEMBL635. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL635

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: PREDNISONE; ChEMBL
ChEMBL ID: CHEMBL635; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Cortan, Cortancyl, Decortisyl, Delta-dome, Deltasone, Fernisone, Liquid pred, Lodotra, Meticorten, Orasone, Paracort, Prednicen-m, Prednisone intensol, Rayos, Servisone, Sterapred; ChEMBL
Other names: 3en3hg4wsw, Decortin, Dehydrocortisone, Metacortandracin, NSC-10023, Prednisona, Prednisone anhydrous, Prednisone tablets, Supercortil; ChEMBL
DrugBank: DB00635; DrugBank
InChIKey: XOFYZVNMUHMLCC-ZPOLXVRWSA-N; ChEMBL
Open Targets' highest stage: Approval, for 70 of its 370 diseases, from ClinicalTrials.gov, DailyMed and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
NR3C1	Glucocorticoid receptor	Glucocorticoid receptor agonist	AGONIST	https://conductscience.org/library/genes/2908

Source ChEMBL

Diseases370

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
prostate cancer	Approval	ClinicalTrials.gov	197	197	https://conductscience.org/library/drugs?q=MONDO_0008315
diffuse large B-cell lymphoma	Phase 3	ClinicalTrials.gov	192	192	https://conductscience.org/library/drugs?q=MONDO_0018905
acute lymphoblastic leukemia	Phase 3	ClinicalTrials.gov	109	109	https://conductscience.org/library/drugs?q=MONDO_0004967
non-Hodgkin lymphoma	Phase 3	ClinicalTrials.gov	76	76	https://conductscience.org/library/drugs?q=MONDO_0018908
plasma cell myeloma	Phase 3	ClinicalTrials.gov	66	66	https://conductscience.org/library/drugs?q=MONDO_0009693
Hodgkins lymphoma	Phase 3	ClinicalTrials.gov	44	44	https://conductscience.org/library/drugs?q=MONDO_0004952
follicular lymphoma	Phase 3	ClinicalTrials.gov	42	42	https://conductscience.org/library/drugs?q=MONDO_0018906
mature T-cell and NK-cell non-Hodgkin lymphoma	Phase 3	ClinicalTrials.gov	35	35	https://conductscience.org/library/drugs?q=MONDO_0000430
mantle cell lymphoma	Phase 3	ClinicalTrials.gov	30	30	https://conductscience.org/library/drugs?q=MONDO_0018876
rheumatoid arthritis	Approval	DailyMed	72	26	https://conductscience.org/library/drugs?q=MONDO_0008383

1 to 10 of 370Source Open Targets

See all 370 diseases

Trials1,416

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 26 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 457 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02883049	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	Phase 3	5,949	2024-03-12	prednisone	Its name	ClinicalTrials.gov
NCT00075725	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Phase 3	3,154	2015-08-06	prednisone	Its name	ClinicalTrials.gov
NCT00408005	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	Phase 3	1,895	2019-06-20	prednisone	Its name	ClinicalTrials.gov
NCT00025259	Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease	Phase 3	1,734	2017-03-07	prednisone	Its name	ClinicalTrials.gov
NCT02261727	Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study	Phase 4	1,670	2021-08-12	prednisone	Its name	ClinicalTrials.gov
NCT01287741	A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)	Phase 3	1,418	2017-08-17	prednisone	Its name	ClinicalTrials.gov
NCT01332968	A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)	Phase 3	1,401	2017-06-07	prednisone	Its name	ClinicalTrials.gov
NCT01949337	Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer	Phase 3	1,311	2020-06-01	prednisone	Its name	ClinicalTrials.gov
NCT00519285	Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer	Phase 3	1,224	2013-10-10	prednisone	Its name	ClinicalTrials.gov
NCT01715285	A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)	Phase 3	1,209	2018-10-15	prednisone	Its name	ClinicalTrials.gov

1 to 10 of 1,416

See all 1,416 trials

Comparisons in its trials379

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events	269 of 701	312 of 702	1,403	NCT01287741	Trial comparisons
Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: deaths from any cause	111 of 692	104 of 698	1,390	NCT01332968	Trial comparisons
Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events	309 of 692	361 of 698	1,390	NCT01332968	Trial comparisons
Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): Number of Participants Who Has Experienced at Least One Toxicity (Defined as a Grade 3 or Higher Adverse Event Deemed at Least Possibly Related to Treatment)	167 of 657	287 of 654	1,311	NCT01949337	Trial comparisons
Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): deaths from any cause	372 of 657	339 of 654	1,311	NCT01949337	Trial comparisons
Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): serious adverse events	232 of 657	269 of 654	1,311	NCT01949337	Trial comparisons
Aflibercept vs Placebo: serious adverse events	331 of 611	184 of 598	1,209	NCT00519285	Trial comparisons
Abiraterone Acetate vs Placebo: Number of Patients Achieving a Prostate-Specific Antigen Decline >=50%	232 of 797	22 of 398	1,195	NCT00638690	Trial comparisons
Cabazitaxel 20 mg/m^2 vs Cabazitaxel 25 mg/m^2: serious adverse events	177 of 580	257 of 595	1,175	NCT01308580	Trial comparisons
Placebo + Prednisone vs Orteronel + Prednisone: Number of Participants With Best Pain Response	72 of 365	166 of 734	1,099	NCT01193257	Trial comparisons

1 to 10 of 379

See all 379 comparisons in its trials

Papers from its trials1,146

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41035796	RESULT	1	PubMed
40897521	RESULT	1	PubMed
40751881	RESULT	1	PubMed
40167581	RESULT	1	PubMed
39934967	RESULT	1	PubMed
39874233	RESULT	1	PubMed
39353506	RESULT	1	PubMed
39211989	RESULT	1	PubMed
38963459	RESULT	1	PubMed
38943232	RESULT	1	PubMed

1 to 10 of 1,146

See all 1,146 papers from its trials

Tests in its trials2

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Go/No-Go Task	1	1	ConductCognition
Paced Visual Serial Addition Test	1	0	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL635

GET https://conductscience.org/api/drugs/v1/CHEMBL635/diseases?page=2

API reference For AI assistants